Deregulation of microRNA expression in follicular-cell-derived human thyroid carcinomas
- PMID: 19942715
- DOI: 10.1677/ERC-09-0217
Deregulation of microRNA expression in follicular-cell-derived human thyroid carcinomas
Abstract
Carcinoma of the thyroid gland is an uncommon cancer, but one of the most frequent malignancies of the endocrine system. Most thyroid cancers are derived from the follicular cells. Follicular carcinoma is considered more malignant than papillary thyroid carcinoma (PTC), and anaplastic thyroid cancer (ATC) is one of the most lethal human cancers. Even though several genetic lesions have been already described in human thyroid cancer, particularly in the papillary histotype, the mechanisms underlying the development of these neoplasias are still far from being completely elucidated. Some years ago, several studies were undertaken to analyze the expression of microRNAs (miRNAs or miRs) in thyroid carcinoma to evaluate a possible role of their deregulation in the process of carcinogenesis. These studies showed an aberrant microRNA expression profile that distinguishes unequivocally among PTC, ATC, and normal thyroid tissue. Here, other than summarizing the current findings on microRNA expression in human thyroid carcinomas, we discuss the mechanisms by which microRNA deregulation may play a role in thyroid carcinogenesis, and the possible use of microRNA knowledge in the diagnosis and therapy of thyroid neoplasms.
Similar articles
-
Can the microRNA signature distinguish between thyroid tumors of uncertain malignant potential and other well-differentiated tumors of the thyroid gland?Endocr Relat Cancer. 2011 Sep 13;18(5):579-94. doi: 10.1530/ERC-10-0283. Print 2011 Oct. Endocr Relat Cancer. 2011. PMID: 21778212
-
Down-regulation of transcription elogation factor A (SII) like 4 (TCEAL4) in anaplastic thyroid cancer.BMC Cancer. 2006 Nov 1;6:260. doi: 10.1186/1471-2407-6-260. BMC Cancer. 2006. PMID: 17076909 Free PMC article.
-
MicroRNA deregulation in human thyroid papillary carcinomas.Endocr Relat Cancer. 2006 Jun;13(2):497-508. doi: 10.1677/erc.1.01209. Endocr Relat Cancer. 2006. PMID: 16728577
-
Genetic mutations in thyroid carcinoma.Minerva Endocrinol. 2009 Mar;34(1):11-28. Minerva Endocrinol. 2009. PMID: 19209125 Review.
-
Micro-RNAs in thyroid neoplasms: molecular, diagnostic and therapeutic implications.J Clin Pathol. 2009 Nov;62(11):978-85. doi: 10.1136/jcp.2008.063909. Epub 2009 Jul 21. J Clin Pathol. 2009. PMID: 19625289 Review.
Cited by
-
[Pathobiology of the microRNA system].Pathologe. 2012 Feb;33(1):70-8. doi: 10.1007/s00292-011-1469-4. Pathologe. 2012. PMID: 21792603 Review. German.
-
Pathogenic mechanisms of deregulated microRNA expression in thyroid carcinomas of follicular origin.Thyroid Res. 2011 Aug 3;4 Suppl 1(Suppl 1):S1. doi: 10.1186/1756-6614-4-S1-S1. Thyroid Res. 2011. PMID: 21835047 Free PMC article.
-
miR-451a is underexpressed and targets AKT/mTOR pathway in papillary thyroid carcinoma.Oncotarget. 2016 Mar 15;7(11):12731-47. doi: 10.18632/oncotarget.7262. Oncotarget. 2016. PMID: 26871295 Free PMC article. Review.
-
Serum miR-375 for Diagnostic and Prognostic Purposes in Medullary Thyroid Carcinoma.Front Endocrinol (Lausanne). 2021 Mar 29;12:647369. doi: 10.3389/fendo.2021.647369. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 33854485 Free PMC article.
-
miR-26a and its target CKS2 modulate cell growth and tumorigenesis of papillary thyroid carcinoma.PLoS One. 2013 Jul 5;8(7):e67591. doi: 10.1371/journal.pone.0067591. Print 2013. PLoS One. 2013. Retraction in: PLoS One. 2021 Apr 13;16(4):e0250313. doi: 10.1371/journal.pone.0250313. PMID: 23861775 Free PMC article. Retracted.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials